search
Back to results

Bausch & Lomb Ophthalmic Viscosurgical Device (OVD) Dispersive (DVisc40)

Primary Purpose

Cataract

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Bausch & Lomb DVisc40
Alcon VISCOAT®
Sponsored by
Bausch & Lomb Incorporated
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cataract

Eligibility Criteria

45 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • The subject must be at least 45 years old and have a clinically documented diagnosis of age-related non-complicated cataract that is considered amenable to treatment with standard phacoemulsification cataract extraction and IOL implantation.

    2. The subject must have the capability to provide written informed consent on the Institutional Review Board (IRB)/Ethics Committee (EC) approved Informed Consent Form (ICF) and provide authorization as appropriate for local privacy regulations.

    3. The subject must be willing and able to return for all scheduled follow-up examinations through 90 days following surgery.

Study #877 Protocol DVisc40 28JUL2017 V1.0 CONFIDENTIAL Page 16 of 53 4. The subject must have clear intraocular media other than the cataract in the operative eye.

Exclusion Criteria:

  • 1. The subject has participated in any drug or device clinical investigation within 30 days prior to entry into this study and/or during the period of study participation.

    2. The subject has any corneal pathology (e.g., significant scarring, guttata, inflammation, edema, dystrophy, etc.) in the operative eye.

    3. The subject has anterior segment pathology likely to increase the risk of an adverse outcome for phacoemulsification cataract surgery (e.g., pseudoexfoliation syndrome, synechiae, iris atrophy, inadequate dilation, shallow anterior chamber, traumatic cataract, lens subluxation) in the operative eye.

    4. The subject has any condition which prevents reliable specular microscopy in the operative eye.

Sites / Locations

  • Valeant Site 01

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Bausch & Lomb DVisc40

Alcon VISCOAT®

Arm Description

Ophthalmic viscosurgical device

Ophthalmic viscosurgical device

Outcomes

Primary Outcome Measures

Percent Change in Mean Epithelial Cell Density (ECD)
Percentage of Participants With Postoperative Intraocular Pressure of at Least 30 mm Hg

Secondary Outcome Measures

Full Information

First Posted
November 17, 2017
Last Updated
September 24, 2021
Sponsor
Bausch & Lomb Incorporated
search

1. Study Identification

Unique Protocol Identification Number
NCT03511638
Brief Title
Bausch & Lomb Ophthalmic Viscosurgical Device (OVD) Dispersive (DVisc40)
Official Title
A Study to Document the Safety and Effectiveness of a New OVD When Compared to a Control OVD
Study Type
Interventional

2. Study Status

Record Verification Date
September 2021
Overall Recruitment Status
Completed
Study Start Date
May 9, 2018 (Actual)
Primary Completion Date
April 1, 2019 (Actual)
Study Completion Date
April 1, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bausch & Lomb Incorporated

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A Study to Document the Safety and Effectiveness of a New OVD When Compared to a Control OVD
Detailed Description
This is a multicenter, controlled, randomized, monocular trial evaluating the safety and effectiveness of the Bausch & Lomb DVisc40 dispersive OVD compared to the Alcon VISCOAT® dispersive OVD when used in cataract surgery. Subjects will be randomized to one of the two treatment groups in a 1:1 ratio (DVisc40:VISCOAT®).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cataract

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
a multicenter, controlled, randomized, monocular trial of Bausch & Lomb DVisc40 (test) OVD compared to the currently marketed Alcon VISCOAT® (control) OVD
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
372 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Bausch & Lomb DVisc40
Arm Type
Experimental
Arm Description
Ophthalmic viscosurgical device
Arm Title
Alcon VISCOAT®
Arm Type
Active Comparator
Arm Description
Ophthalmic viscosurgical device
Intervention Type
Device
Intervention Name(s)
Bausch & Lomb DVisc40
Intervention Description
Ophthalmic viscosurgical device
Intervention Type
Device
Intervention Name(s)
Alcon VISCOAT®
Intervention Description
Ophthalmic viscosurgical device
Primary Outcome Measure Information:
Title
Percent Change in Mean Epithelial Cell Density (ECD)
Time Frame
Day 90
Title
Percentage of Participants With Postoperative Intraocular Pressure of at Least 30 mm Hg
Time Frame
90 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The subject must be at least 45 years old and have a clinically documented diagnosis of age-related non-complicated cataract that is considered amenable to treatment with standard phacoemulsification cataract extraction and IOL implantation. 2. The subject must have the capability to provide written informed consent on the Institutional Review Board (IRB)/Ethics Committee (EC) approved Informed Consent Form (ICF) and provide authorization as appropriate for local privacy regulations. 3. The subject must be willing and able to return for all scheduled follow-up examinations through 90 days following surgery. Study #877 Protocol DVisc40 28JUL2017 V1.0 CONFIDENTIAL Page 16 of 53 4. The subject must have clear intraocular media other than the cataract in the operative eye. Exclusion Criteria: 1. The subject has participated in any drug or device clinical investigation within 30 days prior to entry into this study and/or during the period of study participation. 2. The subject has any corneal pathology (e.g., significant scarring, guttata, inflammation, edema, dystrophy, etc.) in the operative eye. 3. The subject has anterior segment pathology likely to increase the risk of an adverse outcome for phacoemulsification cataract surgery (e.g., pseudoexfoliation syndrome, synechiae, iris atrophy, inadequate dilation, shallow anterior chamber, traumatic cataract, lens subluxation) in the operative eye. 4. The subject has any condition which prevents reliable specular microscopy in the operative eye.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anya Loncaric
Organizational Affiliation
Bausch Health Americas, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Valeant Site 01
City
San Diego
State/Province
California
ZIP/Postal Code
22434
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Bausch & Lomb Ophthalmic Viscosurgical Device (OVD) Dispersive (DVisc40)

We'll reach out to this number within 24 hrs